Fresh off a failed takeover bid that would have lowered its taxes and diversified its product lineup drug maker AbbVie Inc is hoping for a Christmas gift regulatory approval of its first significant new product in a decade The North Chicago Ill company is awaiting a decision from the US Food and Drug Administration this month about whether it can start marketing a multidrug regimen for the liver disease hepatitis C The
  